|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00422500 |
|
Date of registration:
|
12/01/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Longitudinal Study of Multiple Symptoms in Advanced Lung Cancer
|
|
Scientific title:
|
Longitudinal Study of the Prevalence, Severity, and Interference of Multiple Symptoms in Advanced Lung Cancer |
|
Date of first enrolment:
|
November 2003 |
|
Target sample size:
|
204 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00422500 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Xin Shelley Wang, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
M.D. Anderson Cancer Center |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
1. Is an adult > 18 years of age
2. Is diagnosed with Stage III or IV Lung cancer
3. Is scheduled for a new chemotherapy regimen. Patients who have received prior
chemotherapy are eligible.
4. Is English- or Spanish-speaking
5. Currently lives in the United States
Exclusion Criteria:
1. Does not have access to telephones
2. Is unable to use the telephone interactive system
3. Has a current diagnosis of psychosis or dementia
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Lung Cancer
|
|
Intervention(s)
|
|
Behavioral: Questionnaire
|
|
Behavioral: Telephone Interactive System
|
|
Other: Blood Samples
|
|
Primary Outcome(s)
|
|
Longitudinal Data on Symptom Patterns + Severity
[Time Frame: Total weekly IVR assessment period 18 weeks, generally include 6 cycles of chemotherapy and 2-3 assessments of response to chemotherapy.]
|
|
Secondary ID(s)
|
|
2003-0701
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|